% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • harboursnug harboursnug Oct 30, 2013 5:46 PM Flag

    Ohad Hammer - Oct 29th.

    "I intend to keep a position in SNTA as I am a strong believer in Hsp90 as a class of drugs and SNTA’s drug appears to have an optimal clinical profile (potent with no ocular toxicities)."

    Also Slide 22 in the presentation is less robust than previous analysis but it doesn’t mean the Phase 3 trial will fail.

0.2682-0.0118(-4.21%)Jun 29 4:00 PMEDT